These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 26341360

  • 1. Selective modulation of thrombin-activatable fibrinolysis inhibitor (TAFI) activation by thrombin or the thrombin-thrombomodulin complex using TAFI-derived peptides.
    Plug T, Marquart JA, Marx PF, Meijers JC.
    J Thromb Haemost; 2015 Nov; 13(11):2093-101. PubMed ID: 26341360
    [Abstract] [Full Text] [Related]

  • 2. A role for arginine-12 in thrombin-thrombomodulin-mediated activation of thrombin-activatable fibrinolysis inhibitor.
    Plug T, Kramer G, Meijers JC.
    J Thromb Haemost; 2014 Oct; 12(10):1717-25. PubMed ID: 25066897
    [Abstract] [Full Text] [Related]

  • 3. Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity.
    Zhou X, Weeks SD, Ameloot P, Callewaert N, Strelkov SV, Declerck PJ.
    J Thromb Haemost; 2016 Aug; 14(8):1629-38. PubMed ID: 27279497
    [Abstract] [Full Text] [Related]

  • 4. Generation of a stable thrombin-activatable fibrinolysis inhibitor deletion mutant exerting full carboxypeptidase activity without activation.
    Zhou X, Declerck PJ.
    J Thromb Haemost; 2015 Jun; 13(6):1084-9. PubMed ID: 25773535
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Modulation of TAFI function through different pathways--implications for the development of TAFI inhibitors.
    Gils A, Ceresa E, Macovei AM, Marx PF, Peeters M, Compernolle G, Declerck PJ.
    J Thromb Haemost; 2005 Dec; 3(12):2745-53. PubMed ID: 16359512
    [Abstract] [Full Text] [Related]

  • 8. Monoclonal antibodies targeting the antifibrinolytic activity of activated thrombin-activatable fibrinolysis inhibitor but not the anti-inflammatory activity on osteopontin and C5a.
    Semeraro F, Ammollo CT, Gils A, Declerck PJ, Colucci M.
    J Thromb Haemost; 2013 Dec; 11(12):2137-47. PubMed ID: 24134522
    [Abstract] [Full Text] [Related]

  • 9. Identification of a thrombomodulin interaction site on thrombin-activatable fibrinolysis inhibitor that mediates accelerated activation by thrombin.
    Marar TT, Boffa MB.
    J Thromb Haemost; 2016 Apr; 14(4):772-83. PubMed ID: 26816270
    [Abstract] [Full Text] [Related]

  • 10. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties.
    Boffa MB, Wang W, Bajzar L, Nesheim ME.
    J Biol Chem; 1998 Jan 23; 273(4):2127-35. PubMed ID: 9442053
    [Abstract] [Full Text] [Related]

  • 11. Generation and characterization of a highly stable form of activated thrombin-activable fibrinolysis inhibitor.
    Marx PF, Havik SR, Marquart JA, Bouma BN, Meijers JC.
    J Biol Chem; 2004 Feb 20; 279(8):6620-8. PubMed ID: 14660622
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Role of isoleucine residues 182 and 183 in thrombin-activatable fibrinolysis inhibitor.
    Marx PF, Havik SR, Bouma BN, Meijers JC.
    J Thromb Haemost; 2005 Jun 20; 3(6):1293-300. PubMed ID: 15946220
    [Abstract] [Full Text] [Related]

  • 14. The roles of selected arginine and lysine residues of TAFI (Pro-CPU) in its activation to TAFIa by the thrombin-thrombomodulin complex.
    Wu C, Kim PY, Manuel R, Seto M, Whitlow M, Nagashima M, Morser J, Gils A, Declerck P, Nesheim ME.
    J Biol Chem; 2009 Mar 13; 284(11):7059-67. PubMed ID: 19074424
    [Abstract] [Full Text] [Related]

  • 15. Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis.
    Bazzi ZA, Lanoue D, El-Youssef M, Romagnuolo R, Tubman J, Cavallo-Medved D, Porter LA, Boffa MB.
    BMC Cancer; 2016 May 24; 16():328. PubMed ID: 27221823
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparative evaluation of stable TAFIa variants: importance of alpha-helix 9 and beta-sheet 11 for TAFIa (in)stability.
    Ceresa E, De Maeyer M, Jonckheer A, Peeters M, Engelborghs Y, Declerck PJ, Gils A.
    J Thromb Haemost; 2007 Oct 24; 5(10):2105-12. PubMed ID: 17666015
    [Abstract] [Full Text] [Related]

  • 18. Generation of a stable activated thrombin activable fibrinolysis inhibitor variant.
    Ceresa E, Van de Borne K, Peeters M, Lijnen HR, Declerck PJ, Gils A.
    J Biol Chem; 2006 Jun 09; 281(23):15878-83. PubMed ID: 16595693
    [Abstract] [Full Text] [Related]

  • 19. Activated thrombin-activatable fibrinolysis inhibitor attenuates the angiogenic potential of endothelial cells: potential relevance to the breast tumour microenvironment.
    Bazzi ZA, Balun J, Cavallo-Medved D, Porter LA, Boffa MB.
    Clin Exp Metastasis; 2017 Feb 09; 34(2):155-169. PubMed ID: 28124276
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.